Slingshot members are tracking this event:

Gilead Begins Phase 3 Study of Eleclazine for Treatment of Long QT-3 Syndrome - Data Readout Expected H1 of 2017 - Terminated

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details The Phase 3 study of Eleclazine for the treatment in patients with Long QT-3 syndrome is projected to complete February 2017, with a data readout expected in the first half of 2017.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 24, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Study, Eleclazine, Gs-6615, Long Qt-3 Syndrom, Data Readout